Form 4: Korro Bio Inc. Executive Acquires Stock Options

Jeffrey Cerio, General Counsel of Korro Bio, Inc., reports the acquisition of stock options.

Summary

• On February 3, 2025, Jeffrey Cerio, the General Counsel of Korro Bio, Inc., acquired stock options for 29,000 shares.
• The exercise price of these options is $33.50.
• The options vest in 48 equal monthly installments starting February 3, 2025, contingent upon continued service.
• The expiration date for these options is February 2, 2035.
• Following the transaction, Cerio directly owns derivative securities for 29,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The grant of stock options is generally viewed as a positive sign, indicating confidence in the company's future, but it's a standard practice.

Positives

• The acquisition of stock options by a key executive could signal confidence in the company's future performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel. This grant aligns with standard compensation practices.

Comparison to Industry Standards

• Stock option grants are a common component of executive compensation packages in the biotech industry.
• Companies like Moderna and BioNTech also utilize stock options to incentivize their executives.
• The vesting schedule of 48 months is fairly standard in the industry, aligning with typical retention strategies.

Stakeholder Impact

• Shareholders may view the stock option grant as a way to align management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates